Zoetis (NYSE:ZTS) Coverage Initiated by Analysts at The Goldman Sachs Group

The Goldman Sachs Group began coverage on shares of Zoetis (NYSE:ZTS) in a research report issued to clients and investors on Friday, Marketbeat reports. The firm set a “hold” rating and a $74.00 price target on the stock. The Goldman Sachs Group’s price target points to a potential downside of 6.69% from the stock’s current price.

A number of other brokerages have also recently weighed in on ZTS. Morgan Stanley set a $85.00 price target on Zoetis in a research report on Friday, August 7th. Barclays decreased their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Stifel Nicolaus dropped their target price on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a report on Thursday, August 20th. BNP Paribas Exane lowered their price target on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Finally, Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research note on Tuesday, August 25th. Seven analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $99.14.

Zoetis Stock Up 1.1%

ZTS stock traded up $0.89 during trading on Friday, hitting $79.31. 5,570,530 shares of the company’s stock were exchanged, compared to its average volume of 4,418,894. The business has a 50-day moving average price of $74.03 and a two-hundred day moving average price of $83.49. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock has a market capitalization of $32.77 billion, a price-to-earnings ratio of 13.07, a PEG ratio of 1.85 and a beta of 0.74. Zoetis has a 52-week low of $68.77 and a 52-week high of $148.30.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The firm’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter last year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts expect that Zoetis will post 6.15 EPS for the current year.

Hedge Funds Weigh In On Zoetis

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after buying an additional 3,845,869 shares during the last quarter. State Street Corp lifted its holdings in Zoetis by 1.8% in the second quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after acquiring an additional 343,322 shares during the last quarter. Deutsche Bank AG lifted its holdings in Zoetis by 5.8% in the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after acquiring an additional 319,709 shares during the last quarter. Bank of America Corp DE boosted its stake in Zoetis by 7.3% in the first quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock valued at $571,150,000 after acquiring an additional 327,313 shares during the period. Finally, Van ECK Associates Corp boosted its stake in Zoetis by 7.7% in the second quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock valued at $305,559,000 after acquiring an additional 303,395 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.